UTHR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

817.01M

+11.02%

6.878

+11.12%

817.94M

+2.96%

7.017

+5.83%

847.01M

+6.06%

7.207

+12.43%

Estimates Revision

The market is revising Downward the revenue expectations for United Therapeutics Corporation (UTHR) for FY2025, with the revenue forecasts being adjusted by -0.19% over the past three months. During the same period, the stock price has changed by 8.50%.

Revenue Estimates for FY2025

Revise Downward

-0.19%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.94%

In Past 3 Month

Stock Price

Go Up

+8.50%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast UTHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UTHR is 520.00 USD with a low forecast of 423.00 USD and a high forecast of 600.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

4 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

423.00

Averages

520.00

High

600.00

Current: 0.000

Low

423.00

Averages

520.00

High

600.00

UBS

Buy

maintain

$600 -> $645

2026-01-06

New

Reason

UBS

Price Target

$600 -> $645

2026-01-06

New

maintain

Buy

Reason

UBS raised the firm's price target on United Therapeutics to $645 from $600 and keeps a Buy rating on the shares. The Biotech sector enters 2026 on a cautiously optimistic note, the analyst tells investors in a research note. While capital absorption from secondary offerings is a concern, over $47B of pending capital from potential M&A could offset this, though sustained outperformance will likely require M&A activity to continue outpacing secondaries and IPOs, the firm says.

UBS

Buy

maintain

$580 -> $600

2025-11-06

Reason

UBS

Price Target

$580 -> $600

2025-11-06

maintain

Buy

Reason

UBS raised the firm's price target on United Therapeutics to $600 from $580 and keeps a Buy rating on the shares.

Morgan Stanley

Equal Weight

maintain

$435 -> $447

2025-10-30

Reason

Morgan Stanley

Price Target

$435 -> $447

2025-10-30

maintain

Equal Weight

Reason

Morgan Stanley raised the firm's price target on United Therapeutics to $447 from $435 and keeps an Equal Weight rating on the shares. Despite a Q3 miss, shares traded up following commentary on the call regarding the potential for a Tyvaso rest-of-the-world partnerships following recent Phase 3 IPF data, the analyst noted. During the post Q3 follow up call, management noted that the commentary was meant to suggest that the company is open to partnerships and collaborations, but that there are no active discussions, the analyst tells investors.

RBC Capital

Lisa Walter

Outperform

maintain

$569 -> $587

2025-10-30

Reason

RBC Capital

Lisa Walter

Price Target

$569 -> $587

2025-10-30

maintain

Outperform

Reason

RBC Capital analyst Lisa Walter raised the firm's price target on United Therapeutics to $587 from $569 and keeps an Outperform rating on the shares. The company's Q3 results support the firm's view that Tyvaso will continue to grow irrespective of new market entrants, IPF could double the top-line to over $6B in the next 5 years, and the base business will show resiliency, the analyst tells investors in a research note.

H.C. Wainwright

Andrew Fein

Buy

maintain

$500 -> $525

2025-10-30

Reason

H.C. Wainwright

Andrew Fein

Price Target

$500 -> $525

2025-10-30

maintain

Buy

Reason

H.C. Wainwright analyst Andrew Fein raised the firm's price target on United Therapeutics to $525 from $500 and keeps a Buy rating on the shares following the Q3 report. The firm cites Tyvaso revenue growth and the "strong" early launch of Yutrepia for the target boost.

Jefferies

Roger Song

Buy

maintain

$564 -> $575

2025-10-29

Reason

Jefferies

Roger Song

Price Target

$564 -> $575

2025-10-29

maintain

Buy

Reason

Jefferies analyst Roger Song raised the firm's price target on United Therapeutics to $575 from $564 and keeps a Buy rating on the shares. The firm notes the company put out another revenue record quarter, with Tyvaso as key driver. Also, the company is open to various partnerships such as ex-U.S. for Tyvaso and relinepag with potential to combo with other MOA including Winrevair. Overall, Jefferies believes the set-up is even stronger following the quarter.

Valuation Metrics

The current forward P/E ratio for United Therapeutics Corp (UTHR.O) is 17.48, compared to its 5-year average forward P/E of 12.40. For a more detailed relative valuation and DCF analysis to assess United Therapeutics Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

12.40

Current PE

17.48

Overvalued PE

14.37

Undervalued PE

10.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

6.69

Current EV/EBITDA

10.27

Overvalued EV/EBITDA

8.19

Undervalued EV/EBITDA

5.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

4.80

Current PS

6.38

Overvalued PS

5.41

Undervalued PS

4.19

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

UTHR News & Events

Events Timeline

No data

News

4.0

01-06Yahoo Finance

United Therapeutics Upgraded to Overweight with Price Target of $535.73

8.0

2025-12-31NASDAQ.COM

WYNN Options Volume Surges 148.3% with 19,101 Contracts Traded

4.5

2025-12-24Barron's

S&P 500 Futures Steady in Pre-Market Session; United Therapeutics and Intel Underperform

People Also Watch

Frequently Asked Questions

What is United Therapeutics Corp (UTHR) stock price today?

The current price of UTHR is 483.23 USD — it has decreased -1.55 % in the last trading day.

What is United Therapeutics Corp (UTHR)'s business?

United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

What is the price predicton of UTHR Stock?

What is United Therapeutics Corp (UTHR)'s revenue for the last quarter?

United Therapeutics Corp revenue for the last quarter amounts to 799.50M USD, increased 6.76 % YoY.

What is United Therapeutics Corp (UTHR)'s earnings per share (EPS) for the last quarter?

United Therapeutics Corp. EPS for the last quarter amounts to 7.16 USD, increased 12.05 % YoY.

What changes have occurred in the market's expectations for United Therapeutics Corp (UTHR)'s fundamentals?

How many employees does United Therapeutics Corp (UTHR). have?

United Therapeutics Corp (UTHR) has 1305 emplpoyees as of January 10 2026.

What is United Therapeutics Corp (UTHR) market cap?

Today UTHR has the market capitalization of 20.81B USD.